EFTA Document EFTA01785100

From: Ens, Amanda Sent: Friday, August 5, 2016 5:52 PM To: jeffrey E. Subject: RE: MEGA Action: Post NFP Trades: Hedge US Credit, Buy Financials, Buy USD proxies, Buy Biotech M Jeffrey, is now or sometime this afternoon a good time for you to talk? I'm at or let me know when is a good time for me to call you. Thanks, Amanda Amanda Ens Director Bank of America Merrill Lynch Merrill Lynch, Pierce, Fenner & Smith Incorporated One Bryant Park, 5th Floor, New York, NY 10036 From: jeffrey E. [mailto:[email protected] Sent: Friday, August 05, 2016 11:54 AM To: Ens, Amanda; Richard Kahn Subject: Re: MEGA Action: Post NFP Trades: Hedge US Credit, Buy Financials, Buy USD proxies, Buy Biotech amanda lets talk today On Fri, Aug 5, 2016 at 10:01 AM, Ens, Amanda rote: EFTA_R1_00106912 EFTA01785100 The Tail Hedge: Buy Puts on IG Credit. A Dec LQD 98% Put ($120.00) costs 1.29% ($1.55, ref: $122.80, 7.6 vol, 38 delta) or sell JGBs. MEGA Action: Strong US payroll data risks steepening of US yield curve - tail hedge US credit exposures. Post Strong US Payroll Data we still see a December US rate hike. * Growing hike expectations will steepening the US and Japan yield curves. The question is how do Risk Parity funds handle "The Great Rotation" as US equities continue to look more attractive than Fixed Income? Financials and Healthcare and Technology to outperform Utilities and Staples. USD should also benefit as the US yield curve steepens. There is a chart pack below. What is the Trade? 1. The Tail Hedge: Buy Puts on IG Credit. A Dec LQD 98% Put ($120.00) costs 1.29% ($1.55, ref: $122.80, 7.6 vol, 38 delta) or sell JGBs. 2. Financials Outperformance: Buy Regional Banks Call. A Dec KRE, 103% Call ($42) costs 3.8% ($1.60, ref: $41.65, 23.0 vol, 36 delta) 3. Or buy a 6M ATM worst-of {XLF (financials) call, XLU (utilities) put) for - 1.38% (65% discount to the average vanilla option) 4. Post earnings — Buy Healthcare & Biotech on improved outlook: Buy Calls on Bio-Tech Index. A Dec 104% ($310) IBB Call costs $12.70 (4.1%, ref $296.00, 26.0 vol, 41 delta) 5. USD Strength Trade: Short the BAML "Weak USD Winners Equity Custom Basket", MLDIUSDC Index. Rationale US Payroll data was a very strong report showing that the economy can resume a higher trajectory of growth into the second half of the year and the Fed can deliver a hike in December. 2 EFTA_R1_00106913 EFTA01785101 1) NFP was up 255K with net positive revisions of 18K. The 6month moving average of 189K suggests a solid pace of growth. 2) Household jobs surged 420K, reversing the recent few months of weakness. This offset the increase in the labor force participation to 62.8 from 62.7%, which is an encouraging sign for the longer run trajectory of job growth. 3) Average hourly earnings increased 0.3%, leaving the yoy rate unchanged at 2.6%, showing that wages are sticking at a higher pace. 4) The Unemployment rate held at 4.9% while the underemployment rate (U6) increased to 9.7%. 5) Professional & business services saw the strongest job growth of 70,000, though this sector tends to account for a good portion of job growth generally. Only mining and logging (-7k) and information services (Ok) were weak. Post Q2 earnings results, Health Care is now in a strong position to outperform <http://rsch.baml.com/r?q=-- f3Kv0H2hhlw6fcYbuRtA&e=jeevacation%40gmail.com&h=7Ws4Wg> . The sector saw more positive than negative revisions to estimates on a three-month basis, more positive than negative revisions to sales forecasts and management has been most positive in guidance. The Nasdaq Biotechnology Index (NBI) has surpassed S&P500 (up 13% vs. 5%) since the end of 1Q thanks to increased M&A activity and solid 2Q earnings reported by the large-cap biotech companies as a group <http://rsch.baml.com/r?q=DcR3HFJAJ9GrI8M4aKdamg&e=jeevacation%40gmail.com&h=oE91Sw> . Recent NBI rally suggests a "real" turn in market sentiment post major sector sell-off beginning last August. 62% of S&P 500 companies have beaten on EPS, 52% have beaten on sales and 40% have beaten on both compared to full-quarter historical averages of 53%, 57% and 35%, respectively. "Global Equity Volatility Insights <http://rsch.baml.com/r?q=GCfeDc!MVw2rI8M4aKdamg&e=jeevacation%40gmail.com&h=1H7UoA>" from June 28 and suggests risk parity fund leverage is high and we do not think the relationships have changed significantly. As correlation between bonds and SPX increases, risk parity leverage increases. The Bank of Japan's "comprehensive assessment" in Sep MPM is creating intense speculation <http://rsch.baml.com/r?q=0,nrXISChBkWrI8M4aKdamg&e=jeevacationc/040gmail.com&h=Hiu8QQ> . Bol may make QQE more flexible which would enhance policy sustainability risking steeper yield curve, stronger yen and weaker equity but bank shares to rise. If the BoJ does move to make policy more flexible, we think the focus will be on JGBs, rather than on negative interest rates. Chart Pack: 3 EFTA_R1_00106914 EFTA01785102 Nasdaq Bio Tech Index: Buy Calls on Bio-Tech US Investment Grade ETF, (LQD in white) and (Shares Outstanding in Green). Buy Puts on IG Credit. In JGB Futures, 150.60 is an important level for all global fixed income. Regional Bank ETF (KRE): Buy Calls on KRE Short the BAML "Weak USD Winners Equity Custom Basket' This chart is a danger for risk parity funds as bond/equity correlation swings positive. 4 EFTA_R1_00106915 EFTA01785103 Greg Kaldor Managing Director US MEGA (Macro Equity & Global Alpha) Bank of America Merrill Lynch This message, and any attachments, is for the intended recipient(s) only, may contain information that is privileged, confidential and/or proprietary and subject to important terms and conditions available at http://www.bankofamerica.com/emaildisclaimer <http://www.bankofamerica.com/emaildisclaimer> . If you are not the intended recipient, please delete this message. 2046442 This message, and any attachments, is for the intended recipient(s) only, may contain information that is privileged, confidential and/or proprietary and subject to important terms and conditions available at http://www.bankofamerica.com/emaildisclaimer <http://www.bankofamerica.com/emaildisclaimer> . If you are not the intended recipient, please delete this message. <http://rsch-bems- tr. baml.com/q/k_JsMBs9ln liqHZexGTRCQ—/AAAAAQA—/RgRZhyCoPkEIA0vEkF4AsNhCCgADqJ ukV5i i4BNSFWpIZXZ hY2 F0aW9uO.GdtYWIsLmNvbQIRBAAAAABHmXsibmEtZSI6IjA4MDUxMDAxODY4MzI4ODE6MjA0NjO3NillTkEwliwiYXV0aG9y IGVtYWIsl joiYWRtaWSAY29sZH NwYXJam NvbSIsl m NsaWVud F9pZCI6ljUtM DgwNTEwM DE4 NjgzMjg4MToyM DQ2N Dc2LU hOQTAiLCJ0ZW1wbGE0ZSI6ImRIZmElbH Rfd6VtcGxhdGUifQ— > 2046476 please note The information contained in this communication is confidential, may be attorney-client privileged, may constitute inside information, and is intended only for the use of the addressee. It is the property of JEE Unauthorized use, disclosure or copying of this communication or any part thereof is strictly prohibited and may be unlawful. If you have 5 EFTA_R1_00106916 EFTA01785104 received this communication in error, please notify us immediately by return e-mail or by e-mail to [email protected] <mailto:[email protected]> , and destroy this communication and all copies thereof, including all attachments. copyright -all rights reserved This message, and any attachments, is for the intended recipient(s) only, may contain information that is privileged, confidential and/or proprietary and subject to important terms and conditions available at http://www.bankofamerica.com/emaildisclaimer. If you are not the intended recipient, please delete this message. 6 EFTA_R1_00106917 EFTA01785105